Verastem Oncology
MA - NeedhamBiotechnology
Focus: Verastem Oncology is a mid-cap biotech focused on cancer stem cell-targeting therapies, with lead asset in ovarian cancer approaching Phase 3 completion. Based in Needham, MA, the company operates at clinical-stage scale with a narrow but specialized pipeline.
Profile data last refreshed 3h ago · AI intelligence enriched 3w ago
Open Jobs
14+5 this month
Growing — net +5 jobs in 30d
10 jobs added vs 5 removed. Steady team buildout.
Should You Work at Verastem Oncology?
AI assessmentVerastem offers focused oncology expertise and clinical-stage upside in cancer stem cells, but limited pipeline diversity and financial opacity present career risk.
Why Work Here
- Lead product (avutometinib + defactinib copack) has FDA approval and GROWTH lifecycle status with LOE not until 2042, offering long runway
- Active hiring across 10 open roles with emphasis on Medical Affairs (3 positions) and Biostatistics (2 positions), signaling active clinical execution phase
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
AVMAPKI FAKZYNJA CO-PACK
Growing
GROWTH16.1yr
Dual MEK/FAK inhibitor combination approved for low-grade serous ovarian cancer, targeting KRAS-mutant and FAK-dependent tumors with 17-year LOE runway.
Products & Portfolio (1)
Help build intelligence for Verastem Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.